Moderna and Merck Revive mRNA Hopes With Melanoma Success
A personalized vaccine developed by Moderna Inc. and Merck & Co. reduced the recurrence of melanoma in a large, late-stage trial, raising expectations for treating the deadliest form of skin cancer and showing the promise of the embattled mRNA technology. Bloomberg's Sam Fazeli joins to discuss. (Source: Bloomberg)
Quelle est votre réaction ?
Aimer
0
Je n'aime pas
0
Amour
0
Drôle
0
En colère
0
Triste
0
Waouh
0
